SEC Form 10-Q filed by Entero Therapeutics Inc.
$ENTO
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ:ENTO), ("Entero Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of Entero Therapeutics, will moderate the "CEO Insights: Lessons Learned & Strategies for Driving Innovation," CEO Forum which will be held on Tuesday, November 19, 2024 at the Swan Hotel in Orlando, Florida. The session will feature several CEOs as panelists and will be open to senior executives from the Florida Life Science ecosystem. Details of the even
Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey's next-gen, first-in-class ADC-rivalling, nano-immunoconjugates ("NIC") platform and therapeutic products for unmet medical needs in oncology and autoimmune diseases and (ii) Entero's gastrointestinal product pipeline for treating unmet metabolic and rare genetic diseases;The NIC platform technology is invented by and originated from Svetomir N. Markovic, M.D., Ph.D. of Mayo Clinic and is exclusively licensed by Journey with worldwide rights to sublicense;The NIC technology employs the cutting edge cancer drug – nanoparticle albumin-bound ("NAB") paclitaxel Abraxane – as a thera
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
8-K - Entero Therapeutics, Inc. (0001604191) (Filer)
8-K - Entero Therapeutics, Inc. (0001604191) (Filer)
10-Q - Entero Therapeutics, Inc. (0001604191) (Filer)